Synaptogenix Stock Price, News & Analysis

Synaptogenix (Nasdaq: SNPX) announced that Dr. Daniel Alkon will present on "Regenerative Therapeutics" at the Sachs Neuroscience Innovation Forum on March 22, 2022, at 8 am ET. The company reported promising results from its Phase 2 clinical trial of Bryostatin for advanced Alzheimer's patients, showing significant improvements in cognitive scores. The ongoing NIH-supported Phase 2B trial will further investigate Bryostatin’s effects. Synaptogenix is also planning trials for Fragile X syndrome and multiple sclerosis. Presentation details are available online and via social media.

Synaptogenix, Inc. (Nasdaq: SNPX) announced that Dr. Daniel Alkon will present at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022) on March 15, 2022. His presentation covers the clinical results of Bryostatin in treating advanced Alzheimer’s disease and explores its potential for other neurodegenerative disorders, including Parkinson’s and multiple sclerosis. Currently, Bryostatin-1 is under a six-month NIH-sponsored trial for Alzheimer’s. This research could broaden the therapeutic applications of Bryostatin-1 beyond Alzheimer’s.

Synaptogenix, Inc. (SNPX) announced plans to develop Bryostatin-1 for treating multiple sclerosis (MS), marking its third indication alongside Alzheimer's disease and Fragile X syndrome. The company will collaborate with the Cleveland Clinic for a clinical trial focused on safety and efficacy. Bryostatin-1 aims to address synaptic loss in MS patients, a gap in existing therapies. This collaboration aligns with Synaptogenix's strategic goal to advance clinical development through partnerships. The company has a significant safety database from prior studies in over 1,500 individuals.

Synaptogenix, Inc. (Nasdaq: SNPX) announced the publication of its peer-reviewed study in the Journal of Alzheimer's Disease, demonstrating that Bryostatin-1 improves cognition in advanced Alzheimer's Disease (AD) patients compared to baseline, independent of memantine treatment. The study's results, validated through rigorous statistical analysis, potentially justify ongoing NIH support for a Phase 2b clinical trial. CEO Alan Tuchman expressed optimism regarding the trial's ability to verify Bryostatin-1's effectiveness in treating AD, a challenge for other therapeutic strategies.

Synaptogenix, Inc (Nasdaq: SNPX), focused on regenerative therapeutics for neurodegenerative disorders, will participate at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Daniel L. Alkon, President and Chief Scientific Officer, is scheduled to present on September 29 at 2:40 p.m. ET. The company is advancing its candidate, Bryostatin-1, which has shown promise in Alzheimer's and Fragile X syndrome. It holds Orphan Drug Designation for Bryostatin-1 for Fragile X. The FDA-approved candidate has been tested in over 1,500 participants, providing a substantial safety data base for future trials.

Synaptogenix, Inc. (Nasdaq: SNPX) will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. Dr. Daniel Alkon, President and Chief Scientific Officer, will outline the company’s advancements in developing regenerative therapeutics for neurodegenerative disorders. Synaptogenix focuses on Bryostatin-1, which has shown potential in treating Alzheimer's disease and Fragile X syndrome and has a robust safety data background from over 1,500 participants in prior studies.

Synaptogenix, Inc. (Nasdaq: SNPX) announced a memorandum of understanding with Nemours A.I. DuPont Hospital for Children to initiate a clinical trial using Bryostatin to treat Fragile X syndrome. This partnership aims to explore Bryostatin's effects on children and young adults, building on positive preclinical studies that suggest its potential in addressing both intellectual disabilities and behavioral issues associated with Autism Spectrum Disorder. The FDA has previously granted Orphan Drug Status to Bryostatin for its treatment of Fragile X, backing its regenerative properties in neurodegeneration.

Synaptogenix, Inc. (SNPX) announced that its abstract titled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease Patients" is now available for presentation at the Alzheimer's Association International Conference. The analysis indicates significant therapeutic efficacy of Bryostatin in advanced Alzheimer's patients, with a p-value of P<.001, showcasing an improvement of over +4.0 in Severe Impairment Battery scores. The company is also conducting a NIH-sponsored six-month clinical trial to further assess Bryostatin's effects.

Synaptogenix, Inc. (Nasdaq: SNPX) announced a conference call on July 26, 2021, to discuss findings from its abstract presented at the Alzheimer's Association International Conference. The call will feature CEO Dr. Alan Tuchman and President Dr. Daniel Alkon, who will address live Q&A. Synaptogenix is focused on therapies for neurodegenerative diseases, primarily through its lead candidate, Bryostatin-1, which has shown promise in Alzheimer's and Fragile X syndrome. The FDA has granted Orphan Drug Designation for Bryostatin-1 in treating Fragile X syndrome.